-
-
-
-
-
-
-
GlaxoSmithKline (GSK) Misses Q2 EPS by 71c
-
-
-
-
-
-
-
GlaxoSmithKline (GSK) Misses Q4 EPS by 26c
-
-
-
-
-
-
-
Goldman Sachs Starts GlaxoSmithKline (GSK:LN) (GSK) at Neutral
-
-
-
-
-
-
-
GSK fourth-quarter earnings beat expectations amid strong demand for RSV vaccine
-
-
-
-
-
-
-
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
European stocks edge lower; earnings season in full flow
-
-
-
-
-
-
-
Mersana Therapeutics (MRSN) Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056
-
1,204,742 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

